These 20 women are 2018's Fiercest in the life sciences industry.
Read 2018's Fiercest Women in Life Sciences report!
With the help of BioNTech and CEPI's $8.4 million, Imperial College London will work on a self-amplifying RNA vaccine platform.
Here is some other vaccine news of note for the week.
As officials scramble to contain an Ebola outbreak in the Democratic Republic of Congo, the WHO is worried that Merck's vaccine stockpile won't last.
Based in Oxford and slated to open in 2022, the center will focus on creating rapid, cost-effective ways of developing and manufacturing vaccines.
Vaccine trust has fallen in the Philippines since Sanofi's Dengvaxia controversy, and now experts are warning about the threat of measles outbreaks.
A vaccine expert said the anti-vaccine movement is causing its first deaths and subjecting women to cervical cancer for "phony" reasons.
The number of flu shots that passed Chinese regulators so far this season has fallen about 19%, leaving the country short on needed supplies.
After a study showed meningitis B vaccines can protect against gonorrhea, Bexsero maker GSK is weighing whether its vaccine can fight the disease.